The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs downgrades regeneron to neutral amid eylea revenue concerns
UBS has downgraded Regeneron Pharmaceuticals to "Neutral" from "Buy," reducing the price target to $738 due to uncertainties surrounding the Eylea franchise. The firm anticipates a 14% revenue decline for Eylea by 2025 amid increasing competition and limited adoption of high-dose Eylea. While Regeneron's pipeline shows potential in obesity and severe food allergies, long development timelines and the need for proof-of-concept data limit near-term growth prospects.
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.